Shares of PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) were down 3.3% during mid-day trading on Thursday . The company traded as low as $0.7006 and last traded at $0.7266. Approximately 86,486 shares were traded during trading, an increase of 879% from the average daily volume of 8,831 shares. The stock had previously closed at $0.7512.
PharmaCyte Biotech Stock Performance
The stock has a 50-day simple moving average of $0.74 and a 200-day simple moving average of $0.77.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
Featured Stories
- Five stocks we like better than PharmaCyte Biotech
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.jpg){kind=logo}
